Psychedelic therapy and workers' ri 5122321251
https://tempaste.com/5cHsQYIf56B
Berlin, May 16, 2024 - Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe